Member Info for The_Paladin

A significant appointment as CSA to the Al Musella Foundation - and congratulated on LinkedIn by MS.

IB’s website communicates the high quality of our products, and offers some optimism with regard to the GaM trial. However, it is high time for some game changing news from the company.

It has been in a quiescent phase all year with share price decline to 30% of its value at the end of January. The company talks a good investment case, but it is high time for MS et al to walk the talk.

The ongoing onslaught on the share price has started slowly this morning, and will no doubt persist during the day? My investment case remains intact. However, it may take some time before the announcement of appreciable revenues, will halt the share price decline and enable its growth to happen again ?

As with so many other companies, I have misjudged the overall scenario and built my investment here way too soon. GLA.

Max. Thanks for sharing.

My take on this is that it won’t have any impact on IB. The company is barely a minnow in the scale of things. So many companies pay their executives several multiples of our MCap annually. Our share price is anchored at historic lows.

It is frustrating to read that our technology is the best in its class providing highly enhanced images while assisting consultants with their diagnosis, and clinical decisions. Why our sales remain at insignificant levels should be questioned? Our partnerships don’t seem to have helped IB towards effectively marketing and selling our imaging solutions?

We have to set this to one side and wait to see what the Ph1 trial outcome brings? We can but hope that the RNS, when it arrives, won’t be as underwhelming as those issued in recent years.

Bulletin board comments about share prices should not influence investors’ decisions in any shape or scale. I find some contributors’ information about the company - links to articles, videos etc - to be useful and informative. They may have some influence on my decision, nothing more.

It is a very dangerous practice to be caught up by the exuberant ramping on a bulletin board. For example the comments on the Synairgen forum before the results of their disastrous trial were published. Many investors, myself included, lost a lot of capital on that horrendously managed company.

Capai is a different entity. I have a smaller investment here than in the aforementioned total failure of a company. I am neither optimistic, nor am I pessimistic, but my evidence in hand suggests that the share price might well rise to a considerably higher level than where it stands today? GLA.

BB’s analogy describes IB’s situation more accurately than sematic’s c**kroach. This is because it describes the company’s performance in recent years. As we are at an all time low MCap, our resilience against worsening economic conditions isn’t particularly relevant.

The c**kroach description might prove to be valid in the future should our performance improve and the company’s MCap recovers to a respectable value?

Tyke. semantic’s explanation suffered the same re-edit as my earlier comment . I was going to call the process “roaching” until I discovered what that term actually means.

The mere mention of the IB c**kroach has metamorphosed my last contribution exclusively onto lower case text. Let us see if it continues to work its mischief?

hi semantic,

i have just spent the last few minutes reading information sources about c**k roaches. wasted it seems, as i haven’t been able to make sense of your comment? on the bright side, i am on my way to geneva(suisse) this afternoon. if i encounter teb on my subsequent travels, i will ask him if he knows?

c**k roach or otherwise, i am puzzled as to why ib is not attracting more investor interest? the high quality of our imaging technology, with ai “powered”diagnostic tools included, together with our involvement in a very important ph i trial, suggest to me that we should be faring considerably better than at present? with all this potential in hand, has ib somehow metamorphosed into a giant ****roach? this is highly unlikely of course, but our lack of progress is puzzling nevertheless?

further enlightenment for the benefit of lesser mortals like myself would be most appreciated semantic. my thanks in advance for your response. gla.

Additionally, there is currently a significant number of short term traders dipping in and out of small cap companies, with volatile share prices. There has been a lot of fluctuations in Capai’s share price in recent months, which makes it suitable for short term traders.

I sometimes reflect that I might own more shares had I adopted a similar “buy low / sell high” approach. I should add that this is not as easy as it seems to be,in hindsight, otherwise we would all be earning a living from swing trading. Perhaps some contributors on here are doing just that?

Below is an article about the gallium maltolate preparation used by MCW in their Ph I trial, sponsored by Imaging Biometrics. The article is dated April 8, 2022. It is interesting to note that the trial study also received "supporting grants from the Musella Brain Tumor Foundation and the MCW Cancer Center."

There are several stakeholders in this clinical trial, and I have often questioned IB's role? Did the company supply the image enhancing and diagnostic equipment to monitor the patients' progress as they progressed with their treatment? Did they provide additional support? Has this ever been clarified? Am I missing something here?

Importantly for investors, what would IB accrue in the event of a successful outcome to PH I, and subsequent progression to a Ph II and possibly a Ph III trial?

https://www.mcw.edu/newsroom/news-articles/innovative-therapy-that-tricks-and-destroys-cancer-cells-advances-to-clinical-trial

Thank you for sharing max.

Andrew Nencka’s (Director of Centre for Medical Imaging Research, MCW) comment includes the following:

“Dr. Kathleen Schmainda in the Department of Biophysics at the Medical College of Wisconsin recently published research showing how modern brain tumor imaging protocols--which she collaborated to define--are now impacting care for patients with brain metastases. You can see it in AJNR: https://lnkd.in/gh9FzHb7

This work will direct the care of COUNTLESS individuals…”

Presumably, with KS directly involved, and AN a senior employee at MCW, it is IB’s imaging technology that is being utilised?

I agree with other contributors to this forum that IB’s advanced medical imaging is solely commented upon by themselves, and by MCW employees. It is taking far too long to achieve more widespread use? “semantic” has raised the same point on a number of occasions.

Why is this company so undervalued by the market bearing in mind the potential of its imaging technologies and associated tools? Added to this there is also the promising concluded Ph1 GaM trial, currently under review, with the potential for a Ph2 extension?

Back to “semantic”, I recall that further back he quoted 9p as being a realistic valuation of what the company had to offer? In common with “semantic” and others, I fail to understand what is anchoring this company to such a low valuation? Perhaps positive news will bring about the start of a correction? I just hope that there will be no further damaging malarkey perpetrated by a senior individual within the company?

Unfortunately, nothing of note has been announced from the company this year. The share price is 30% of its mid January value.

I still maintain that the annual cash raise is substantially to pay directors’ salaries. I assumed that once the latter was announced again this year, that there wouldn’t be any imminent announcement to improve our prospects. Sadly, I was right on that score.

IB have been producing regular updates on their technology, both on LinkedIn and on X for a considerable time. The major selling points are the superior image quality, and the facility to diagnose the severity of the patient’s condition, and suggest a treatment plan, using AI, thereby assisting the specialist/surgeon and reducing the stress of these overworked consultants. Despite regular messaging from the company, highlighting these advantages, both on social media, and on their website, there is no evidence of a significant improvement in product sales.

The GaM trial has been soft closed, and we can expect to learn about its outcome and the next steps by the end of the year.

I have foolishly remained invested in this company for far too long. It has been one long disappointment thus far. Sadly so many AI based small companies have flourished this year, and this trend is set to continue. Hopefully, we have not missed the bandwagon?

Most of my comments on the GaM trial are derived from the following article, published well over 4 years ago. The stakeholders and their contributory roles are identified as is the broad strategy for the trial, and additional avenues to be explored. How successful has the company been to date in achieving these early aspirations? Several irons remain in the fire, and investors would ideally want further clarification of the progress made in each case. Hopefully sometime this year?

https://appliedradiology.com/articles/phase-i-trial-to-evaluate-safety-efficacy-of-gallium-maltolate-for-glioblastoma-multiforme

Showjumper has summed up the company’s plight in a sentence. If IB’s products are superior to those of our competitors. Surely the wherewithal to market and sell them should be well within the company’s strategic planning ?

I am also concerned by an earlier comment about the GaM trial. There seems to be multiple “ownership”/stakeholders involved? What exactly is the company’s stake in this, and what ultimate pecuniary benefits could the company achieve from a successful outcome to the potential follow up Phase II and Phase III trials? If it is the company’s responsibility to raise the funds for the aforementioned trials, how will it go about achieving the necessary cash raise? When will it be the right time to bring in a partner with the means to accelerate the trials through the various stages? ( I believe that it has taken IB 4 years to gather the Ph I data, and probably until the end of this year to analyse, evaluate, and publish the outcome).

‘Stone checker’ features on IB’s website. However, there has been no encouraging update during the current decade.

https://www.imagingbiometrics.com/what-we-offer/product-services/ib-stonechecker/

https://healthairegister.com/radiology/products/imaging-biometrics-stonechecker

One of my major concerns with this investment is that our current innovative AI led diagnostic technology might follow a similar unsuccessful fate as has Stone checker.? The company’s attempts to highlight the superiority of IB’s systems over those of our competitors have not resulted in significant product sales to date. MS and others within the company are doing what they can, but as things stand there has been little progress in recent years.

More selling has resulted in a 10% drop in the share price to a new all-time low.

This is due to the “all promise and no delivery” IB messages that have been on LinkedIn and elsewhere for longer than I care to remember. We have some decent people on board, but sometimes it feels like being invested in a non-profit making charity, and certainly not a company striving to generate profits to benefit its employees and investors.

Today we were presented with a neutral RNS, but the lack of progress has tipped the balance for some previous investors. Investors have been given vague projections with no clear timelines for far too long. We received an honest appraisal, but the lack of progress on all fronts means that our disastrous plunge for going on three years is set to continue. I hope that the Board will soon realise that the company’s apparent inaction has resulted in a severe depression in its MCap currently < £1.4m.

The situation is worse than I had anticipated. A relatively small number of shares have been sold, but the share price is heading for a new all time low by today’s close, unless there is some buying during the afternoon?

IB’s constant optimism on LinkedIn and elsewhere has not been matched by sales of their technologies, and progress with the P1 trial is slow.

Major positive news is needed to bring about a reversal. Today’s RNS suggests that there is nothing imminently on the horizon? The report implies that we may have to wait until the end of 2025 for a trial update?

I agree with Tyke. The half year report is an honest appraisal of where the company stands IMO. It is disappointing that we are “treading water”, and that further measures are necessary, both with the GaM trial, and with the proliferation of our technologies. The acceptance of the latter within brain scanning centres, and elsewhere is slow, and MS and his team have work on their hands to gain acceptance of the technical advantages of our products.

The publication of the P1 trial results and the next steps resulting from these are our current work in progress. Any positive news on this in the not too distant future would be more than welcome.

Meanwhile, the company continues to move forward. The report is less than we all hoped for, but is a good summary of where we stand at present. Best to maintain optimism IMO, although one seller disposed of some shares within 10 minutes of the RNS announcement. GLA.

Imaging Biometrics is a micro company with 9-11 employees including MS. Is there any wonder why we are unnoticed?

The most recent LinkedIn post last weeks justifies the technical superiority of IB’s products when compared with those of our competitors. Another recent comment supported the view that the AI component of the software majorly assists surgical consultants with their diagnosis thus reducing the risk of burnout. The P1 trial updates have already established the potential of the GaM treatment.

The above have been recurring themes for a number of years. Currently, we have no idea as to when this all round potential will finally come to fruition?

The above sums up my frustration as a LTI. An annual cash raise with associated dilution, mostly to pay directors’ salaries does nothing to promote any optimism! Presumably there would be no need for this measure if there was a major imminent development to be announced?

This RNS is vague, and the measure outlined serves to incentivise IB employees, who are not specified.

The fact that the contact details at the bottom lists three of the Board Members (MS is not listed) under IQ-AI Ltd suggests to me that it may have been cobbled together in a hurry?

As an investor, I am mostly positive about the content as it implies an increase in the share price, although ,as usual, it is impossible to place a time scale on any of this.

Unfortunately, much of the conversation on here is concerned with TEB and a possible stitch up. This does happen, as long term holders of Synairgen discovered at the start of 2025. In that case, the decline that precipitated it was due to the apparent incompetence of their so-called CEO and CSO, and others in their team, who were responsible for a 99.2% fall in the share price over three years. Essentially TFG Holdings, the major shareholders made it impossible for LTIs to participate in a cash raise to initiate a new P2 trial, and a possible recovery to their previous losses.

In the case of IBAI, there is a huge difference in that there is a highly competent team, who have produced leading edge products. The quality of their products has been recognised within their industry, and they provide regular evidence of this on LinkedIn and elsewhere. Further the P1 trial, which they are sponsoring has soft closed and the promising patient data is being analysed, and the next steps are being considered. A half year update on the company's progress is due in mid-August, should they act in accordance with last year's schedule? We may hear more about the P1 trial outcome and what happens next at that point?

I fully understand the seeds of doubt sown by LTIs here. Having experienced the worst possible outcome from the aforementioned previous investment, I am only too aware of the self serving sociopaths that exist within the investment industry, and the fact that they are prepared to totally jettison LTIs to satisfy their greed. Despite my conviction in the sincerity and good intentions of MS, KS and all their associates at IB (Wisconsin), I remain unconvinced that this investment will eventually come good to everyone's benefit? I can only hope to be proven wrong but, at present, there is no way of knowing what might happen in the future? GLA.